Cargando…

HGG-38. DE NOVO PYRIMIDINE SYNTHESIS INHIBITION INDUCES REPLICATION CATASTROPHE MEDIATED CELL DEATH IN DIFFUSE MIDLINE GLIOMA

Diffuse midline gliomas (DMG) are aggressive and lethal pediatric brain tumors that cannot be cured by conventional therapeutic modalities. Using a genome wide CRISPR screen we identified the de novo pyrimidine biosynthesis pathway as a metaboilic vulnerability in DMGs. BAY2402234 is a small molecul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pal, Sharmistha, Kaplan, Jakub, Stopka, Sylwia, Regan, Michael, Kann, Benjamin, Agar, Nathalie, Stiles, Charles, Cooney, Tabitha, Mueller, Sabine, Chowdhury, Dipanjan, Haas-Kogan, Daphne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	High Grade Gliomas
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168089/ http://dx.doi.org/10.1093/neuonc/noab090.102

Ejemplares similares

HGG-23. IN VITRO AND IN VIVO PRECLINICAL DRUG SCREENING OF PROMISING THERAPEUTICS FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Cosentino, Chiara Cianciolo, et al.
Publicado: (2021)

HGG-45. Characterization of spinal diffuse midline gliomas, H3 K28M-mutant
por: Stegat, Lotte, et al.
Publicado: (2022)

HGG-24. PRECLINICAL EFFICACY OF THE BRAIN PENETRANT CYCLIN-DEPENDENT KINASE INHIBITOR ZOTIRACICLIB IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS
por: Mueller, Timothy, et al.
Publicado: (2021)

HGG-50. TWO CASES OF H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA OF CERVICAL SPINAL CORD
por: Kuroha, Masae, et al.
Publicado: (2020)

HGG-03. THE GLYCOSPHINGOLIPIDS METABOLISM IS A NOVEL TARGET IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
por: Paret, Claudia, et al.
Publicado: (2021)

HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022)

HGG-31. Unique case of a bithalamic H3K27-wildtype diffuse midline glioma, EGFR-altered with methylated MGMT
por: Reinecke, James, et al.
Publicado: (2022)

HGG-38. Gliomatosis cerebri/Glioblastoma with discordant histological and molecular profiles - treatment and outcome of a pediatric patient
por: Harrod, Virginia, et al.
Publicado: (2022)

HGG-35. IDENTIFICATION OF G PROTEIN-COUPLED RECEPTOR 17 (GPR17) UP-REGULATION IN PAEDIATRIC H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA AND EXAMINATION OF ITS ROLE IN DIFFUSE MIDLINE GLIOMA CELL LINES
por: Loveson, Katie, et al.
Publicado: (2021)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

HGG-29. How I treat recurrent pediatric high-grade glioma (HGG): A Europe-wide survey study.
por: Perwein, Thomas, et al.
Publicado: (2022)

HGG-58. SIOPE HGG Working Group approach to obtain consensus on management of paediatric high grade glioma across Europe
por: Giraud, Géraldine, et al.
Publicado: (2022)

HGG-38. A COMPARATIVE PROTEOMIC-ANALYSIS OF THE CELL MEMBRANE FRACTIONS OF HISTONE 3 MUTATED BRAIN TUMOURS TO IDENTIFY NOVEL THERAPEUTICS
por: Pickering, James, et al.
Publicado: (2020)

HGG-31. UNIQUE BIOLOGICAL CHARACTERISTICS OF RADIATION-INDUCED GLIOMAS
por: Váňová, Kateřina, et al.
Publicado: (2020)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

HGG-33. EXPLOITING METABOLIC DEFECTS WITH NAMPT INHIBITORS IN DIPG
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
por: Alharbi, Musa, et al.
Publicado: (2020)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

HGG-21. MALIGNANT SYNAPTIC PLASTICITY IN PEDIATRIC HIGH-GRADE GLIOMAS
por: Taylor, Kathryn, et al.
Publicado: (2021)

HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS
por: Boynton, Adam, et al.
Publicado: (2020)

HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA
por: Dubois, Frank, et al.
Publicado: (2020)

HGG-56. Spatial mapping of the tumor micro-environment in pediatric glioma
por: Messiaen, Julie, et al.
Publicado: (2022)

HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas
por: Boynton, Adam, et al.
Publicado: (2022)

HGG-22. Uptake of investigational therapy in children with High Grade Glioma
por: Toledano, Helen, et al.
Publicado: (2022)

HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN
por: Pietsch, Torsten, et al.
Publicado: (2020)

HGG-42. CLINICAL FEATURES AND TREATMENT OUTCOME OF MALIGNANT GLIOMAS IN CHILDREN AND ADOLESCENTS
por: Yonezawa, Hajime, et al.
Publicado: (2020)

HGG-16. EXOSOME-MEDIATED INTER-CLONAL INTERACTIONS IN PEDIATRIC GBM AND DIPG
por: Pericoli, Giulia, et al.
Publicado: (2020)

HGG-41. CHARACTERIZATION OF THE IMMUNE RESPONSE FOLLOWING VARIOUS RADIOTHERAPY TREATMENTS IN GLIOBLASTOMA
por: Cocito, Carolina, et al.
Publicado: (2021)

HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS
por: Haberler, Christine, et al.
Publicado: (2020)

HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin
por: Lazow, Margot A, et al.
Publicado: (2022)

HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma
por: Guerrini-Rousseau, Lea, et al.
Publicado: (2022)

HGG-17. Novel Fusion in Congenital Brainstem Diffuse High-Grade Glioma
por: Norris, Gregory, et al.
Publicado: (2022)

HGG-27. ANTI-CANCER POTENTIAL OF ARGINASE FOR HIGH-GRADE GLIOMA IN VITRO & IN-VIVO
por: Fung, M K L, et al.
Publicado: (2020)

HGG-22. EVALUATING THE REGULATION OF BLOOD-BRAIN BARRIER INTEGRITY IN DIPG MOUSE MODELS
por: Wei, Xin, et al.
Publicado: (2021)

HGG-27. HNRNPA1 SPLICED VARIANT SENSITIZATION EFFECT DISCLOSED IN GLIOMA CELLS
por: Yadav, Ajay
Publicado: (2021)

HGG-14. ACT001 – A PROMISING THERAPEUTIC FOR DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Upton, Dannielle, et al.
Publicado: (2021)

HGG-04. ZINC ENHANCES TEMOZOLOMIDE CYTOTOXICITY IN PEDIATRIC GLIOBLASTOMA MULTIFORME MODEL SYSTEM
por: Toren, Amos, et al.
Publicado: (2020)

HGG-24. HIGH-GRADE GLIOMA WITH A NOVEL FUSION GENE OF VCL-ALK
por: Yamamoto, Shunsuke, et al.
Publicado: (2020)

HGG-08. Lorlatinib for the treatment of ALK fusion positive infant high grade glioma
por: Greenwell, Alyssa, et al.
Publicado: (2022)

HGG-55. An adolescent with a High-Grade Glioma: persuing a specific diagnosis
por: Luz, Inês Romão, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mog9bg8198sqq96f514dii9tri